PT - JOURNAL ARTICLE AU - Davidson, Jennifer A AU - Banerjee, Amitava AU - Smeeth, Liam AU - McDonald, Helen I AU - Grint, Daniel AU - Herrett, Emily AU - Forbes, Harriet AU - Pebody, Richard AU - Warren-Gash, Charlotte TI - Underlying cardiovascular risk and major adverse cardiovascular events after acute respiratory infection: a population-based cohort study of over 4.2 million individuals in England, 2008-2018 AID - 10.1101/2021.03.18.21253890 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.18.21253890 4099 - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253890.short 4100 - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253890.full AB - Background While acute respiratory infections (ARIs) can lead to cardiovascular complications, the effect of underlying cardiovascular risk profile on ARI incidence and cardiovascular complications in those without established cardiovascular disease (CVD) is unknown. Whether to consider individuals at raised cardiovascular risk a priority group for vaccination against respiratory infections therefore remains unclear.Methods We conducted a cohort study in individuals aged 40-64 years without established CVD or a chronic health condition eligible for influenza vaccination, using Clinical Practice Research Datalink GOLD and Aurum data from 01/09/2008-31/08/2018 linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics mortality data from England. We classified cardiovascular risk based on diagnosed hypertension and overall predicted cardiovascular risk estimated using QRISK2 score (≥10% compared with <10%). Using multivariable Poisson regression models, we obtained incidence rate ratios (IRR) for ARI. Among individuals who had an ARI, we then used multivariable Cox regression to obtain hazard ratios (HR) for the risk of major adverse cardiovascular events (MACE) within one year of infection.Findings 4,212,930 individuals were included; 12·5% had hypertension and 14·4% had a QRISK2 score ≥10%. After adjusting for confounders, patients with hypertension (IRR 1·04, 95% CI 1·03-1·05) or QRISK2 score ≥10% (IRR 1·39, 1·37-1·40) had a higher incidence of ARI. Of the 442,408 individuals with an ARI, 4,196 had a MACE within one year of infection. After adjustment, hypertension (HR 1·98, 1·83-2·15) and QRISK2 score ≥10% (HR 3·65, 3·42-3·89) were associated with substantial increased risk of a MACE after infection.Interpretation People without diagnosed CVD but who have raised cardiovascular risk, measured by diagnosed hypertension or, in particular, overall predicted cardiovascular risk, have increased incidence of both ARI and cardiovascular complications following an ARI.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form. A.B. has received grants from Astra Zeneca, UK Research and Innovation (UKRI), and the NIHR. C.W.-G. has received speaker fees from Sanofi Pasteur and participated in a Data Safety Monitoring Board for an investigator-led trial of the effect of influenza vaccination after heart attack on future cardiovascular prognosis (NCT02831608) from Jan 2019- Apr 2020.Funding StatementThis work was funded in whole, or in part, by the Wellcome Trust [201440/Z/16/Z] who fund an Intermediate Clinical Fellowship for C.W.-G. For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This work was also funded by the British Heart Foundation (FS/18/71/33938) who fund a Non-Clinical PhD Studentship for J.A.D. H.I.M is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England (PHE). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or PHE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CPRD Independent Scientific Advisory Committee approved data use for the study (application 19_209). London School of Hygiene and Tropical Medicine provided ethical approval (application 17894).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this study were obtained from the Clinical Practice Research Datalink (CPRD). All CPRD data are available via an application to the Independent Scientific Advisory Committee (see https://www.cprd.com/Data-access). Data acquisition is associated with a fee and data protection requirements.